Structure Advances Obesity Drug as Research Spending Climbs
Cash and short-term investments fell about $200 million sequentially to $1.3 billion.
Structure Therapeutics (GPCR), a clinical-stage biopharmaceutical company developing oral treatments for obesity, advanced aleniglipron into Phase 3 as quarterly research spending climbed.
The first patients were dosed in the ACCOMPLISH-1 and ACCOMPLISH-2 trials, marking a shift into larger and more expensive late-stage development. The studies plan to enroll up to 3,600 and 1,100 patients, respectively, across three active maintenance doses and placebo.
Second-quarter research and development expense rose 83% from a year earlier to $100.1 million, driven by higher clinical-trial, preclinical-development and personnel costs. Total operating expenses increased 68% to $118.6 million.
The higher spending widened Structure’s net loss 72% to $106.2 million from $61.7 million a year earlier. The company didn’t report revenue or per-share results in the supplied operating metrics.
General and administrative expense increased 18% to $18.6 million as Structure expanded personnel and infrastructure and incurred higher professional-services costs. Noncash share-based compensation rose 68% to $12.6 million.
Beyond aleniglipron, Structure added a second oral dual amylin and calcitonin receptor agonist to its disclosed clinical timetable. The company plans to begin a Phase 1 trial of ACCG-3535 in the fourth quarter of 2026.
Structure also appointed John Berrios as chief commercial officer ahead of potential registration and commercialization. Berrios previously led obesity-and-diabetes sales strategy at Novo Nordisk, adding commercial leadership as the company entered its largest clinical program to date.